// App-Quantinova.ai

: Dose Reduction of First and Second Generation TKIs Is Effective in the Maintenance of Major Molecular Response and May Predict Successful Tfr in CML Patients

Researchers

Presenter

  • Simone Claudiani

Principal Investigators

  • Jane Apperley

  • Afzal Khan

  • Richard Szydlo

  • George Nesr

  • George Adams

  • Letizia Foroni

  • Jamshid S Khorashad

  • Dragana Milojkovic

Medical Centers

  • Department of Haematology, Hammersmith Hospital, Imperial Healthcare NHS Trust, London, United Kingdom

  • Centre for Haematology, Department of Medicine, Imperial College London, London, United Kingdom

  • Centre for Haematology, Imperial Collegel, London, United Kingdom

  • Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom

  • Molecular Diagnostics, Imperial College Healthcare NHS Trust, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Bosutinib

  • Nilotinib

  • dasatinib

  • Imatinib

  • IkT001

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved